GenScript FY26 H1 net loss narrows 28.9% to US$ 129.34 million; revenue rises 27.3% to US$ 404.22 million

• GenScript Biotech posted a net loss of US$ 129.34 million in the six months ended June 30, 2026; loss per share was 5.92 US cents.
• Revenue rose 27.3% on an underlying basis to US$ 404.22 million; gross profit climbed 48.0% to US$ 206.71 million.
• Adjusted net profit more than doubled to US$ 62.52 million, reflecting non-HKFRS measures that exclude Legend-related equity accounting impacts.
• The net loss included a US$ 154.9 million equity accounting impact from Legend, including US$ 9.95 million share of loss and US$ 144.96 million non-cash impacts.
• Life Science revenue increased 28.8% to US$ 318.98 million; ProBio revenue rose 34.2% on an underlying basis to US$ 61.11 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260816-12285809), on August 16, 2026, and is solely responsible for the information contained therein.